Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LTRN

Lantern Pharma Inc

May 02 • 04:00PM ET

5.49

Dollar change +0.10
Percentage change 1.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF MEDX IWC AVSC DFAC DCOR

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	26.83%	Shs Outstand	10.72M	Perf Week	0.55%
Market Cap	59.07M	Forward P/E	-	EPS next Y	-1.88	Insider Trans	-19.44%	Shs Float	7.87M	Perf Month	-36.46%
Income	-15.96M	PEG	-	EPS next Q	-0.43	Inst Own	10.30%	Short Float	6.32%	Perf Quarter	29.79%
Sales	0.00M	P/S	-	EPS this Y	-38.32%	Inst Trans	0.92%	Short Ratio	1.50	Perf Half Y	121.37%
Book/sh	3.82	P/B	1.44	EPS next Y	7.38%	ROA	-31.15%	Short Interest	0.50M	Perf Year	10.69%
Cash/sh	3.84	P/C	1.43	EPS next 5Y	-	ROE	-32.93%	52W Range	2.38 - 11.99	Perf YTD	28.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.81%	ROI	-38.96%	52W High	-54.21%	Beta	1.56
Dividend TTM	-	Quick Ratio	16.18	Sales past 5Y	0.00%	Gross Margin	-	52W Low	130.67%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	16.18	EPS Y/Y TTM	-12.02%	Oper. Margin	0.00%	RSI (14)	42.19	Volatility	10.10% 11.52%
Employees	21	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	22.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-24.47%	Payout	-	Rel Volume	0.42	Prev Close	5.39
Sales Surprise	-	EPS Surprise	2.50%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	331.84K	Price	5.49
SMA20	-11.20%	SMA50	-18.47%	SMA200	17.64%	Trades		Volume	137,628	Change	1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

May-02-24 07:30AM	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM	3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM	Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM	Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
09:00AM	Loading…
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
08:01AM	Loading…
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com)
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)
Nov-01-23 08:00AM	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET (Business Wire)
Oct-24-23 04:03PM	The 7 Most Undervalued AI Penny Stocks to Buy: October 2023 (InvestorPlace)
Oct-10-23 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET (Business Wire) +10.32%
Oct-03-23 08:00AM	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma (Business Wire) -8.23%
Sep-29-23 07:40AM	LTRN: Spotlight on LP-184 & 284 (Zacks)
Sep-25-23 08:30AM	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors (Business Wire)
Sep-18-23 09:00AM	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkins Lymphomas (Business Wire)
09:09AM	Loading…
Sep-14-23 09:09AM	The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:00AM	Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkins Lymphomas at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Aug-28-23 05:32PM	3 AI Stocks That Still Trade Under $10 Per Share (InvestorPlace)
08:00AM	Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors (Business Wire)
Aug-23-23 06:00PM	The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023 (InvestorPlace)
Aug-14-23 08:30AM	Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT (Business Wire)
Aug-10-23 08:37AM	LTRN: 2Q:23 Quarterly Update (Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM	Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire)
09:11AM	3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True (InvestorPlace)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE)
08:00AM	Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET (Business Wire)
Aug-01-23 07:30PM	3 AI Stocks to Buy Under $10 in August 2023 (InvestorPlace) +5.62%
Jul-30-23 02:45PM	7 AI Penny Stocks that Could Hit $5 Soon (InvestorPlace)
Jul-17-23 08:00AM	Lantern Pharma to Participate and Present at Multiple Upcoming Conferences (Business Wire)
Jun-26-23 08:30AM	Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkins Lymphomas (Business Wire)
Jun-12-23 08:30AM	Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors (Business Wire) +7.96%
Jun-08-23 09:00AM	Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University (Business Wire)
May-19-23 06:50AM	3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023 (InvestorPlace) +6.38%
May-17-23 08:00AM	Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET (Business Wire)
May-10-23 09:59AM	LTRN: First Harmonic Patient Dosed (Zacks Small Cap Research)
May-09-23 04:01PM	Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +5.66%
May-03-23 09:00AM	Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial (PR Newswire) -6.05%
May-02-23 04:01PM	Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET (Business Wire)
07:30AM	Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound (Business Wire)
Apr-13-23 07:30AM	Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284 (Business Wire)
Mar-28-23 08:00AM	Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer (Business Wire)
Mar-24-23 07:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 11:50AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.)
11:45AM	LTRN: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-21-23 04:01PM	Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars (Business Wire) -5.38%
12:11PM	Q4 2022 Lantern Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 04:01PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights (Business Wire)
Mar-15-23 08:00AM	Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-13-23 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET (Business Wire) +9.30%
06:16AM	Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week (MarketWatch)
06:00AM	Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank (Business Wire)
Mar-09-23 08:00AM	Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors (Business Wire)
Mar-08-23 08:00AM	Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lanterns Drug Candidates, Featuring Zoltan Szallasi, M.D. (Business Wire)
Mar-06-23 08:00AM	Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers (Business Wire)
Mar-02-23 08:00AM	Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials (Business Wire)
Feb-27-23 08:00AM	Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352 (Business Wire)
Feb-21-23 12:10PM	7 AI Penny Stocks That Could Skyrocket in 2023 (InvestorPlace)
Feb-15-23 08:00AM	Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates (Business Wire)
Feb-01-23 04:55AM	LTRN: LP-184 & LP-284 in the Spotlight (Zacks Small Cap Research)
Jan-17-23 08:00AM	Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184s Phase 1 Clinical Trial in Q2 2023 (Business Wire)
Jan-05-23 08:59AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma (Business Wire) -11.94%
Dec-31-22 06:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-15-22 08:00AM	Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting (Business Wire)
Dec-13-22 08:00AM	Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) (Business Wire)
Dec-02-22 01:46PM	10 Best Artificial Intelligence Stocks Under $10 (Insider Monkey)
08:00AM	Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET (GlobeNewswire)
Nov-22-22 08:00AM	Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting (Business Wire)
Nov-08-22 04:48AM	LTRN: Harmonic Screening Underway (Zacks Small Cap Research)
Nov-07-22 04:01PM	Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights (Business Wire)
Nov-02-22 08:00AM	Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4 (Business Wire)
Oct-31-22 08:00AM	Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET (Business Wire)
Oct-25-22 08:00AM	Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences (Business Wire)
Oct-21-22 07:00AM	Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET (Business Wire)
Oct-20-22 07:59AM	Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300 (Business Wire)
Oct-13-22 10:48AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.) +5.89%
Oct-11-22 04:00PM	Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET (ACCESSWIRE)
Oct-05-22 08:00AM	Lantern Pharma to Present at Upcoming Investor Conferences (Business Wire)
Sep-23-22 08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-19-22 08:50AM	Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D. (Business Wire)
Sep-14-22 12:05PM	Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate (Benzinga) +5.51%
08:50AM	Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer (Business Wire)
Aug-30-22 09:00AM	Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwrights 24th Annual Global Investment Conference in September 2022 (Business Wire) -6.37%
Aug-19-22 08:30AM	Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) -5.56%
Aug-09-22 08:20AM	LTRN: Music to Our Ears: Harmonic to Start (Zacks Small Cap Research)

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kreis Leslie W.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:30 PM
Fletcher Aaron G.L.	10% Owner	Jan 17 '24	Sale	4.20	58,889	247,334	73,646	Jan 19 04:31 PM
Kreis Leslie W.	10% Owner	Nov 29 '23	Sale	3.44	145,348	499,997	217,553	Dec 01 06:00 AM
Fletcher Aaron G.L.	10% Owner	Nov 29 '23	Sale	3.44	145,348	499,997	217,553	Dec 01 06:01 AM

Open in Screener

AZTR

Azitra Inc

May 02 • 04:00PM ET

0.2199

Dollar change -0.0048
Percentage change -2.14	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	44.28%	Shs Outstand	28.80M	Perf Week	-0.09%
Market Cap	6.33M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	3.23%	Shs Float	16.05M	Perf Month	-6.43%
Income	-12.64M	PEG	-	EPS next Q	-	Inst Own	0.19%	Short Float	1.27%	Perf Quarter	-81.04%
Sales	0.69M	P/S	9.18	EPS this Y	83.61%	Inst Trans	-	Short Ratio	0.29	Perf Half Y	-86.26%
Book/sh	0.24	P/B	0.91	EPS next Y	0.00%	ROA	-	Short Interest	0.20M	Perf Year	-
Cash/sh	0.06	P/C	3.52	EPS next 5Y	-	ROE	-	52W Range	0.16 - 5.18	Perf YTD	-76.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-363.52%	52W High	-95.75%	Beta	-
Dividend TTM	-	Quick Ratio	1.54	Sales past 5Y	149.87%	Gross Margin	37.97%	52W Low	37.01%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	1.54	EPS Y/Y TTM	-	Oper. Margin	-1110.66%	RSI (14)	45.61	Volatility	7.47% 11.40%
Employees	10	Debt/Eq	0.31	Sales Y/Y TTM	-	Profit Margin	-1842.44%	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	5.01%	Payout	-	Rel Volume	0.46	Prev Close	0.22
Sales Surprise	-	EPS Surprise	-11.11%	Sales Q/Q	5.88%	Earnings	Mar 15 AMC	Avg Volume	704.96K	Price	0.22
SMA20	5.46%	SMA50	-1.54%	SMA200	-84.62%	Trades		Volume	331,949	Change	-2.14%

Apr-22-24 04:30PM	Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting (Business Wire)
Apr-18-24 04:15PM	Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024 (Business Wire) -5.10%
Mar-15-24 04:15PM	Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-16-24 04:05PM	Azitra, Inc. Announces Closing of Public Offering (Business Wire) +6.01%
Feb-13-24 10:09PM	Azitra, Inc. Announces Pricing of Public Offering (Business Wire) -24.33%
09:00AM	Loading…
Jan-16-24 09:00AM	Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US (Business Wire) +32.50%
Jan-03-24 09:00AM	Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference (Business Wire) +11.42%
Nov-14-23 04:30PM	Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates (Business Wire)
Oct-16-23 08:00AM	Azitra to Present at the ThinkEquity Conference (Business Wire) +7.59%
Aug-29-23 08:00AM	Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 04:05PM	Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates (PR Newswire)
Jul-19-23 04:05PM	Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors (PR Newswire)
Jul-11-23 04:05PM	Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer (PR Newswire)
Jun-21-23 06:46PM	Azitra, Inc. Announces Closing of Initial Public Offering (PR Newswire) +9.62%
Jun-15-23 07:04PM	Azitra, Inc. Announces Pricing of Initial Public Offering (PR Newswire)

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Staskey Norm	Chief Financial Officer	Mar 29 '24	Buy	0.21	47,600	10,034	51,100	Apr 01 09:51 PM
Salva Francisco D.	President and CEO	Feb 13 '24	Buy	0.30	333,300	99,990	338,300	Feb 15 08:38 PM
Whitfill Travis	Chief Operating Officer	Feb 13 '24	Buy	0.30	15,000	4,500	334,500	Feb 15 08:42 PM
Staskey Norm	Chief Financial Officer	Feb 13 '24	Buy	0.30	3,300	990	3,500	Feb 15 08:39 PM
Kreis Leslie W.	10% Owner	Jun 21 '23	Buy	5.00	600,000	3,000,000	1,747,670	Jun 23 09:38 PM
Fletcher Aaron G.L.	10% Owner	Jun 21 '23	Buy	5.00	600,000	3,000,000	1,747,670	Jun 23 09:37 PM

Open in Screener

INAB

IN8bio Inc

May 02 • 04:00PM ET

1.02

Dollar change -0.02
Percentage change -1.92	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.01	Insider Own	32.38%	Shs Outstand	43.29M	Perf Week	-1.92%
Market Cap	44.16M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.00%	Shs Float	29.27M	Perf Month	-1.92%
Income	-30.01M	PEG	-	EPS next Q	-0.17	Inst Own	27.31%	Short Float	1.75%	Perf Quarter	-15.00%
Sales	0.00M	P/S	-	EPS this Y	36.80%	Inst Trans	-22.50%	Short Ratio	1.50	Perf Half Y	4.09%
Book/sh	0.58	P/B	1.77	EPS next Y	9.41%	ROA	-89.91%	Short Interest	0.51M	Perf Year	-51.89%
Cash/sh	0.49	P/C	2.07	EPS next 5Y	-	ROE	-125.90%	52W Range	0.65 - 3.48	Perf YTD	-26.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.62%	ROI	-105.97%	52W High	-70.69%	Beta	0.05
Dividend TTM	-	Quick Ratio	4.57	Sales past 5Y	0.00%	Gross Margin	-	52W Low	56.92%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	4.57	EPS Y/Y TTM	25.79%	Oper. Margin	0.00%	RSI (14)	44.06	Volatility	7.07% 8.94%
Employees	31	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.90
Option/Short	No / Yes	LT Debt/Eq	0.14	EPS Q/Q	33.21%	Payout	-	Rel Volume	0.57	Prev Close	1.04
Sales Surprise	-	EPS Surprise	-43.51%	Sales Q/Q	-	Earnings	Mar 14 AMC	Avg Volume	341.31K	Price	1.02
SMA20	-3.18%	SMA50	-9.01%	SMA200	-11.42%	Trades		Volume	196,108	Change	-1.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	Loading…
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
07:00AM	Loading…
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
08:00AM	Loading…
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)
Dec-08-22 07:00AM	IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma (GlobeNewswire) -5.26%
Nov-10-22 07:30AM	IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.38%
Nov-03-22 09:10AM	IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-22 07:30AM	IN8bio to Present at November Investor Conferences (GlobeNewswire)
Sep-27-22 07:30AM	IN8bio to Present at Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-15-22 07:30AM	IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 (GlobeNewswire)
Sep-13-22 07:30AM	IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.98%
Sep-08-22 07:30AM	IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board (GlobeNewswire) +6.58%
Aug-30-22 04:15PM	IN8bio to Present at September Investor and Scientific Conferences (GlobeNewswire) +39.39%
Aug-19-22 09:20AM	IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-16-22 04:15PM	IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Aug-12-22 04:15PM	IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.57%
Aug-11-22 10:05PM	IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -10.00%
Jul-27-22 07:00AM	IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients (GlobeNewswire) +9.10%
Jul-21-22 07:00AM	Newly Issued European Patent Broadens IN8bios Drug Resistant Immunotherapy (DRI) Platform (GlobeNewswire)
Jul-12-22 08:00AM	IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development (GlobeNewswire) -5.28%
Jul-10-22 09:12AM	Is IN8bio (NASDAQ:INAB) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-30-22 04:15PM	IN8bio to Present at July Investor and Scientific Conferences (GlobeNewswire) -6.22%
Jun-08-22 08:00AM	IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences (GlobeNewswire)
Jun-06-22 07:00AM	IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 (GlobeNewswire)
May-17-22 07:00AM	IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell Off-the-Shelf Induced Pluripotent Stem Cell Platform (GlobeNewswire) -11.43%
May-12-22 08:00AM	IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-22 08:00AM	IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting (GlobeNewswire)
May-04-22 08:00AM	IN8bio to Present at May Investor and Scientific Conferences (GlobeNewswire) +8.80%
May-03-22 11:00AM	Bullish IN8bio, Inc. (NASDAQ:INAB) investors are yet to receive a pay off on their US$1.0m bet (Simply Wall St.) +11.11%
Apr-13-22 08:30AM	IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments (GlobeNewswire)
Apr-05-22 04:15PM	IN8bio to Present at April Investor and Scientific Conferences (GlobeNewswire)
Mar-28-22 08:00AM	IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Mar-17-22 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +9.42%
Mar-04-22 07:00AM	IN8bio to present at March Investor and Scientific Conferences (GlobeNewswire)
Feb-10-22 05:36PM	IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit (GlobeNewswire)
Jan-31-22 12:29PM	We're Not Very Worried About IN8bio's (NASDAQ:INAB) Cash Burn Rate (Simply Wall St.) +12.33%
Jan-10-22 07:00AM	IN8bio to Present at Upcoming January Investor Conferences (GlobeNewswire) +7.35%
Jan-06-22 07:00AM	IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme (GlobeNewswire) +7.11%
Dec-16-21 07:00AM	IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Dec-09-21 04:30PM	IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer (GlobeNewswire) -7.95%
Nov-16-21 07:00AM	IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer (GlobeNewswire)
Nov-11-21 07:00AM	IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors (GlobeNewswire)
Nov-10-21 04:15PM	IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:00AM	IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO (GlobeNewswire)
Nov-01-21 09:28AM	Possible turnaround for IN8bio, Inc. (NASDAQ:INAB) insiders, still down US$241k after a US$1.0m shopping spree (Simply Wall St.)
Oct-27-21 07:00AM	IN8bios Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme (GlobeNewswire) -7.46%
Oct-04-21 04:15PM	IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021 (GlobeNewswire)
Sep-10-21 04:15PM	IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-30-21 07:00AM	IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-11-21 08:00AM	IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Aug-04-21 08:00AM	IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors (GlobeNewswire)
Jul-30-21 07:00AM	IN8bio Announces Pricing of Initial Public Offering (GlobeNewswire)

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Graff Jeremy R.	Director	Sep 13 '23	Buy	0.95	2,500	2,375	2,500	Sep 15 04:51 PM
McCall Patrick	Chief Financial Officer	Aug 25 '23	Buy	1.03	1,000	1,030	6,263	Aug 28 04:43 PM
Ho William Tai-Wei	President and CEO	Aug 24 '23	Buy	1.05	23,800	24,990	2,339,545	Aug 28 04:42 PM

Open in Screener

CGTX

Cognition Therapeutics Inc

May 02 • 04:00PM ET

1.98

Dollar change +0.03
Percentage change 1.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CGTX Cognition Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	22.70%	Shs Outstand	32.17M	Perf Week	2.59%
Market Cap	77.22M	Forward P/E	-	EPS next Y	-1.20	Insider Trans	0.06%	Shs Float	30.15M	Perf Month	0.51%
Income	-25.79M	PEG	-	EPS next Q	-0.25	Inst Own	17.02%	Short Float	0.73%	Perf Quarter	-13.54%
Sales	0.00M	P/S	-	EPS this Y	-13.40%	Inst Trans	-0.79%	Short Ratio	1.10	Perf Half Y	76.79%
Book/sh	0.76	P/B	2.60	EPS next Y	-22.54%	ROA	-60.26%	Short Interest	0.22M	Perf Year	24.53%
Cash/sh	0.77	P/C	2.58	EPS next 5Y	-	ROE	-79.69%	52W Range	0.90 - 3.49	Perf YTD	7.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.09%	ROI	-105.37%	52W High	-43.27%	Beta	1.53
Dividend TTM	-	Quick Ratio	3.37	Sales past 5Y	0.00%	Gross Margin	-	52W Low	119.98%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	3.37	EPS Y/Y TTM	3.78%	Oper. Margin	0.00%	RSI (14)	53.55	Volatility	5.80% 7.20%
Employees	28	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-48.01%	Payout	-	Rel Volume	0.27	Prev Close	1.95
Sales Surprise	-	EPS Surprise	15.62%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	199.92K	Price	1.98
SMA20	1.51%	SMA50	2.46%	SMA200	17.98%	Trades		Volume	55,392	Change	1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-21	Initiated	Oppenheimer	Outperform	$22
Nov-03-21	Initiated	B. Riley Securities	Buy	$27

Apr-29-24 07:30AM	Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (GlobeNewswire)
Apr-22-24 07:30AM	Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease (GlobeNewswire)
Apr-02-24 07:30AM	Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 07:30AM	Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024 (GlobeNewswire)
Mar-27-24 09:31AM	Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:13AM	Loading…
01:13AM	Q4 2023 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 11:53AM	CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-24 07:30AM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-14-24 04:05PM	Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock (GlobeNewswire)
Mar-11-24 08:16PM	Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock (GlobeNewswire)
04:05PM	Cognition Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-06-24 07:30AM	Cognition Therapeutics Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies (GlobeNewswire)
Feb-26-24 07:30AM	Cognition Therapeutics to Present at the TD Cowen Health Care Conference (GlobeNewswire)
Feb-06-24 08:47AM	New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812 (GlobeNewswire)
07:30AM	Loading…
Jan-04-24 07:30AM	Cognition Therapeutics CEO Issues Letter to Shareholders (GlobeNewswire)
Nov-16-23 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens (GlobeNewswire)
Nov-15-23 07:30AM	Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases (GlobeNewswire)
Nov-07-23 07:30AM	Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Nov-03-23 06:00AM	Cognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 07:30AM	Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.42%
Oct-27-23 07:30AM	Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer's Disease at CTAD (GlobeNewswire)
Oct-24-23 04:30PM	Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD (GlobeNewswire)
Oct-16-23 07:30AM	Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications (GlobeNewswire) +8.93%
Sep-07-23 07:45AM	Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD (GlobeNewswire)
Aug-30-23 08:00AM	Cognition Therapeutics Announces Participation in Upcoming September Conferences (GlobeNewswire) +12.95%
Aug-09-23 09:09AM	Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? (Simply Wall St.)
Aug-08-23 09:52PM	Q2 2023 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-02-23 07:30AM	Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023 (GlobeNewswire)
07:30AM	Loading…
Jul-11-23 07:30AM	Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD (GlobeNewswire)
Jul-05-23 07:30AM	Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimers Disease (GlobeNewswire) -8.47%
Jun-28-23 07:00AM	Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimers Disease (GlobeNewswire) -12.80%
Jun-27-23 07:17PM	Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023 (GlobeNewswire) -11.03%
Jun-20-23 07:30AM	Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimers Disease Approaches (GlobeNewswire) -5.33%
Jun-02-23 07:30AM	Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences (GlobeNewswire) +12.05%
May-23-23 09:40AM	Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year? (Zacks)
07:30AM	Cognition Therapeutics Latest Episode of Conversations Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC (GlobeNewswire)
May-18-23 03:53PM	A Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's A Oligomer Displacement (Benzinga) +14.94%
07:30AM	Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces A Oligomers from Binding to Neuronal Synapses in Alzheimers Disease (GlobeNewswire)
May-04-23 04:05PM	Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-01-23 07:30AM	Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer (GlobeNewswire) -7.30%
Apr-19-23 07:30AM	Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023 (GlobeNewswire)
Apr-12-23 07:30AM	Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases (GlobeNewswire)
Mar-28-23 07:30AM	Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimers Disease Processes (GlobeNewswire)
Mar-27-23 08:00AM	Cognition Therapeutics Announces New Episode of Conversations Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies (GlobeNewswire) +7.73%
07:12AM	Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 11:03PM	Q4 2022 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-23 08:00AM	Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimers Disease at AD/PD 2023 (GlobeNewswire)
Mar-16-23 12:18PM	UPDATE Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results (GlobeNewswire) +13.33%
07:30AM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-15-23 07:30AM	Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD (GlobeNewswire)
Mar-07-23 08:00AM	Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference (GlobeNewswire) +8.38%
Feb-22-23 08:00AM	Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimers Disease (GlobeNewswire) +6.42%
Feb-21-23 07:30AM	Cognition Therapeutics Announces New Episode of Conversations Podcast: What if its not Alzheimers? The Caregivers Perspective on Lewy Body Dementia (GlobeNewswire) -9.17%
Feb-20-23 08:50AM	Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Feb-09-23 08:00AM	Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimers Disease (GlobeNewswire)
Dec-22-22 08:00AM	Cognition Therapeutics Announces New Conversations Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimers Disease (GlobeNewswire)
Dec-21-22 04:05PM	Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023" (GlobeNewswire) -5.53%
Dec-15-22 08:00AM	First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812 (GlobeNewswire)
Dec-01-22 08:38AM	Cognition Therapeutics, Inc.'s (NASDAQ:CGTX) market cap surged US$46m last week, individual investors who have a lot riding on the company were rewarded (Simply Wall St.) -25.93%
07:30AM	Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD (GlobeNewswire)
Nov-28-22 08:00AM	Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD (GlobeNewswire)
Nov-21-22 08:00AM	Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series (GlobeNewswire) +5.44%
Nov-15-22 12:55PM	Cognition Therapeutics Announces Closing of Public Offering (GlobeNewswire) +16.94%
Nov-14-22 08:00AM	Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.06%
Nov-10-22 08:00AM	Cognition Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
Oct-12-22 08:00AM	Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S. (GlobeNewswire)
Oct-11-22 08:00AM	Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development (GlobeNewswire) -5.71%
Sep-29-22 07:30AM	Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference (GlobeNewswire) +13.79%
Sep-27-22 07:32AM	Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial (GlobeNewswire)
Sep-06-22 07:32AM	Cognition Therapeutics Announces Participation in September Investment Conferences (GlobeNewswire)
Aug-11-22 06:56AM	We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-22 07:00AM	Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-22 04:02PM	Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimers Disease Processes (GlobeNewswire) +62.16%
02:30PM	EXCLUSIVE: Cognition Therapeutics Shares Biomarker Data From Alzheimer's Candidate (Benzinga)
Aug-03-22 04:05PM	Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 (GlobeNewswire) +6.73%
Jul-19-22 08:00AM	Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimers Disease (GlobeNewswire)
Jun-23-22 07:30AM	Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812 (GlobeNewswire) +9.33%
Jun-08-22 07:30AM	Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-02-22 04:01PM	Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation (GlobeNewswire) -5.66%
May-13-22 07:30AM	Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference (GlobeNewswire) +12.74%
May-11-22 07:00AM	Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -7.41%
May-04-22 05:54PM	CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
04:01PM	Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022 (GlobeNewswire)
May-03-22 08:00AM	Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD (GlobeNewswire) -7.96%
May-02-22 11:18AM	Insiders who bought in the last 12 months lose an additional US$189k as Cognition Therapeutics, Inc. (NASDAQ:CGTX) drops to US$63m (Simply Wall St.) +13.36%
Apr-25-22 04:01PM	Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration (GlobeNewswire)
08:00AM	Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference (GlobeNewswire)
Apr-06-22 07:30AM	Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-22 07:00AM	Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire) -10.44%
Mar-22-22 08:00AM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results (GlobeNewswire) -8.67%
Mar-10-22 07:30AM	Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimers Disease at AD/PD 2022 (GlobeNewswire)
Mar-08-22 08:00AM	Cognition Therapeutics Announces Participation in March Investment Conferences (GlobeNewswire)
Feb-08-22 07:30AM	Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics (GlobeNewswire)
Jan-10-22 07:30AM	Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022 (GlobeNewswire)
Jan-08-22 07:01AM	Companies Like Cognition Therapeutics (NASDAQ:CGTX) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-04-22 07:30AM	Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinsons Disease (GlobeNewswire) +10.24%
Dec-21-21 07:30AM	Cognition Therapeutics to Participate in Next-Generation Alzheimers Disease Panel at Virtual Biotech Showcase on January 11, 2022 (GlobeNewswire) +7.25%

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ricciardi Lisa	CEO & President	Mar 14 '24	Buy	1.75	5,700	9,975	291,345	Mar 14 04:34 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LTRN

Lantern Pharma Inc

AZTR

Azitra Inc

INAB

IN8bio Inc

CGTX

Cognition Therapeutics Inc

Upgrade your FINVIZ experience